Enovis Corporation (ENOV)
NYSE: ENOV · Real-Time Price · USD
24.51
+0.19 (0.78%)
Mar 6, 2026, 4:00 PM EST - Market closed

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
1.30B1.25B
United States Revenue Growth
3.99%8.10%
Foreign Locations Revenue
952.72M861.95M
Foreign Locations Revenue Growth
10.53%55.35%
Revenue (Total)
2.25B2.11B
Revenue (Total) Growth
6.66%23.46%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
U.S. Bracing & Support Revenue
486.24M469.32M
U.S. Bracing & Support Revenue Growth
3.61%2.89%
U.S. Other P&R Revenue
271.64M270.74M
U.S. Other P&R Revenue Growth
0.33%0.34%
International P&R Revenue
379.09M357.90M
International P&R Revenue Growth
5.92%2.02%
Total Prevention & Recovery Revenue
1.14B1.10B
Total Prevention & Recovery Revenue Growth
3.55%1.97%
U.S. Reconstructive Revenue
537.46M505.62M
U.S. Reconstructive Revenue Growth
6.30%18.58%
International Reconstructive Revenue
573.62M504.05M
International Reconstructive Revenue Growth
13.80%147.06%
Total Reconstructive Revenue
1.11B1.01B
Total Reconstructive Revenue Growth
10.04%60.16%
Total Medical Technology Revenue
2.25B2.11B
Total Medical Technology Revenue Growth
6.66%23.46%
Revenue (Total)
2.25B2.11B
Revenue (Total) Growth
6.66%23.46%

Adjusted EBITDA

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Prevention & Recovery Adjusted EBITDA
163.09M159.60M
Prevention & Recovery Adjusted EBITDA Growth
2.19%4.65%
Reconstructive Adjusted EBITDA
239.91M216.92M
Reconstructive Adjusted EBITDA Growth
10.60%85.84%
Operating Income (Total)
-1.12B-775.72M

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Prevention & Recovery Capital Expenditures
28.86M34.00M
Prevention & Recovery Capital Expenditures Growth
-15.12%29.02%
Reconstructive Capital Expenditures
168.51M146.71M
Reconstructive Capital Expenditures Growth
14.86%53.03%
Total Medical Technology Capital Expenditures
197.38M180.71M
Total Medical Technology Capital Expenditures Growth
9.22%47.86%
Updated Feb 26, 2026. Data Source: Fiscal.ai.